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EGFRvIII, a mutated form of EGFR, plays a prominent role in tumorigenesis, but the underlying mechanisms
have remained elusive. In this issue of Cancer Cell, Weiss and colleagues implicate phosphorylation of
EGFRvIII by EGFR and the consequent phosphorylation of STAT3 as a signaling axis that drives transforma-
tion in glioblastoma.Glioblastoma multiforme (GBM) is the
most common neuroepithelial brain tumor
and is among the most clinically aggres-
sive of all human tumor types. The
epidermal growth factor receptor (EGFR)
is often amplified in GBM and provides a
potential therapeutic target. In a subset
of the cases, EGFR amplification is
accompanied by gene rearrangement,
the most common of which is EGFR
variant III (EGFRvIII), which contains an
in-frame deletion of 801 bp of coding
sequence from exons 2 to 7. This results
in a loss of EGFR’s extracellular domain,
which is involved in dimerization and
ligand binding and has been correlated
with ligand-independent and constitutive
phosphorylation of the receptor (Nishi-
kawaetal., 1994;Huangetal., 2009). Inter-
estingly, EGFRvIII’s tyrosine kinase activ-
ity has been reported to be relatively low
(Ekstrand et al., 1991), but the variant re-
ceptor is known toexhibit increasedstabil-
ity due to reduced interaction with Casitas
B lineage (Cbl) proteins (Schmidt et al.,
2003). Since EGFRvIII expression is tumor
specific, there is considerable interest in
developing targeted therapies, but the
results so far with small molecular inhibi-
tors have been disappointing in the clinic.
The transcription factor STAT3 is known
to be involved in astrocyte differentiation
in the developing brain andmayplay either
a pro-oncogenic or a tumor-suppressive
role dependingon the genetic background
of the tumor. STAT3 suppresses transfor-
mation induced by PTEN loss. In contrast,
STAT3 supports oncogenesis when coex-
pressed with EGFRvIII and has been
shown to form a complex with EGFRvIII
in the nucleus, resulting in EGFRvIII-induced transformation of glial cells (de la
Iglesia et al., 2008). However, the role of
EGFRvIII in gliomagenesis is complex,
and thereareseveral keyunresolvedques-
tions. A striking observation using pan-
EGFR- and EGFRvIII-specific antibodies
is that while EGFRoverexpression is wide-
spread and homogeneous among the
tumor cells in most cases of GBM, immu-
nohistochemical staining forEGFRvIII typi-
cally shows patchy tumor positivity of only
aminority of the tumor cells. HowEGFRvIII
promotes oncogenesis in the setting of
such tumor heterogeneity is not fully un-
derstood, although it may be related to
paracrine effects. EGFRvIII induces the
secretionof IL-6andLIF,which in turn acti-
vate gp130 in a paracrine fashion that
results in EGFR activation in neighboring
cells (Inda et al., 2010). Additionally, in hu-
man tumors, overexpression of EGFRvIII
is usually observed not in isolation, but
in combination with amplification of the
wild-type (WT) receptor, suggesting selec-
tive pressure for expression of both EGFR
species in cancer.
In this issue ofCancer Cell, a paper from
theWeiss laboratory (Fanetal., 2013) char-
acterizes the interaction between EGFR
and EGFRvIII and sheds some light on
cooperation between these species that
accounts for some of these findings (sum-
marized inFigure1).Theyfirstdemonstrate
coexpression of EGFR and EGFRvIII in a
subpopulationof tumor cells. Asexpected,
in EGFRvIII-positive cases, EGFRvIII stain-
ing was detected only in a minority of
tumor cells. Importantly, while there were
many EGFR-positive, EGFRvIII-negative
tumor cells and some double-positive
cells, EGFR-negative, EGFRvIII-positiveCancer Cell 24tumorcellswerenotdetected,whichmight
suggest selective pressure for expres-
sion of WT EGFR protein in the setting of
EGFRvIII expression. To demonstrate
functional significance, Fan et al. showed
that EGFR and EGFRvIII cooperate in
cellular transformation assays, with the
combination being more powerful than
either expressed alone. Transformation
was further increased in the presence of
EGF. This finding was corroborated in
tumor xenograft experiments.
To evaluate downstream signaling, Fan
et al. (2013) first examined AKT and ERK
activation and found no appreciable dif-
ferences among cells overexpressing
EGFR, EGFRvIII, or both. In contrast,
STAT3 and STAT5 phosphorylation was
markedly increased in cells expressing
both EGFR and EGFRvIII (double positive)
compared to cells overexpressing either
one alone. In human tumors, p-STAT3
was also highest in GBM cells that coex-
pressed EGFR and EGFRvIII. Importantly,
nuclear expression of p-STAT3 colocal-
ized with double-positive regions in these
tumors. Examination of data from The
Cancer Genome Atlas showed a correla-
tion of EGFR/EGFRvIII double positivity
with a network involving PKC and PLC,
both of which are STAT3 dependent.
Surprisingly, while EGFRvIII is known to
be ligand independent, Fan et al. found
that the addition of EGF ligand resulted
in increased phosphorylation of EGFRvIII
in cells expressing both EGFR and
EGFRvIII. This suggested that ligand-
dependent activation of EGFR caused
EGFR to cross-phosphorylate EGFRvIII.
The authors characterize themechanisms

















Figure 1. Mechanism of Cooperation between EGFR and EGFRvIII
The binding of EGF to its cognate receptor, EGFR, leads to activation of downstream kinase pathways,
including RAS/RAF/MEK/MAPK and PI3K/AKT. The EGFRvIII mutant is constitutively active and can
induce signal transduction in the absence of EGF by heterodimeric association with WT EGFR. The coop-
erative activity of EGFR and EGFRvIII is not restricted to the membrane since numerous studies have
shown cytoplasmic and nuclear functions of these growth factor receptors that become internalized via
endocytic vesicles. Fan et al. (2013) show a heterodimerization-independent mechanism of oncogenesis
induced by an EGFR-EGFRvIII-STAT3 signaling axis. In the presence of EGF, EGFR undergoes dimeriza-
tion (not shown) and activation, as multiple Tyr residues are phosphorylated (shown as yellow circle).
Activated WT EGFR subsequently phosphorylates EGFRvIII (shown as orange circle), triggering nuclear
transport of EGFRvIII, enhanced phosphorylation of STAT3, and increased EGFRvIII-STAT3 interaction
in the nucleus, which drive transformation.
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alleles of EGFR engineered to accept
ATP analogs not efficiently used by WT
kinases. EGFRas3-positive cells demon-
strated EGF-dependent phosphorylation
of EGFRas3, whereas cells transduced
with EGFRvIIIas3 showed baseline phos-
phorylation of EGFRvIIIas3, as expected.
In cells transduced with both EGFRas3
and EGFRvIII, an as3-allele-selective
inhibitor 4TB blocked both EGFRas3
and EGFRvIII phosphorylation, implying
that EGFRvIII phosphorylation is EGFR
dependent. In the ‘‘reverse’’ experiment,
in which cells transduced with EGFR and
EGFRvIIIas3 were used, 4TB treatment
had no effect on EGFR phosphorylation.
Furthermore, using a kinase-dead
allele of EGFRvIII, Fan et al. (2013) show
that p-STAT3 levels were dependent on
EGFRvIII phosphorylation. Further experi-
ments showed that kinase-dead EGFRvIII
was phosphorylated byWT EGFR, but the
converse was not true, since the presence
of ‘‘normal’’ EGFRvIII failed to phosphor-
ylate kinase-dead EGFR. These results
suggested that EGFRvIII is a substrate of404 Cancer Cell 24, October 14, 2013 ª2013EGFR. Subcellular fractionation experi-
ments showed that EGF treatment of cells
transduced with EGFR and EGFRvIII re-
sulted in both cytoplasmic and nuclear
localization of phosphorylated EGFRvIII.
Using an EGFRvIII allele defective for
nuclear entry, Fan et al. found that
STAT phosphorylation is dependent on
nuclear accumulation of phosphorylated
EGFRvIII. Immunoprecipitation experi-
ments showed an EGFRvIII-STAT3 com-
plex that was dependent on activated
EGFR. Finally, combined treatment with
EGFR and STAT inhibitors enhanced
apoptosis in double-positive cells above
baseline levelmore potently than the com-
bined treatment did in ingle-positive cells,
indicating a therapeutic opportunity.
Overall, these results (1) account for the
clinical finding that EGFRvIII is seen only in
the context of EGFR amplification, (2) sug-
gest directionality of EGFR to EGFRvIII
signal transduction, and (3) showselective
enhanced STAT activation only in the
presence of an intact EGFR-EGFRvIII
signaling axis in tumor cells. Several inter-
esting and important questions are raisedElsevier Inc.by these findings. While others have
reported physical binding of EGFR and
EGFRvIII (Luwor et al., 2004), Fan et al.
were unable to demonstrate this by co-
immunoprecipitation, raising the question
as to what other mechanisms are involved
in EGFRvIII activation by EGFR. Next, the
fact that EGFRvIII is present only in iso-
lated tumor cells, combined with the fact
that STAT signaling has been implicated
in tumor-initiating cells (TICs) (Guryanova
et al., 2011), raises the intriguing question
as towhether EGFRvIII serves as amarker
for these TICs in a subset of GBM. Finally,
whether EGFRvIII-positive tumors are
truly addicted to this variant allele is an
open question. EGFRvIII is seen only in
the presence of EGFR, but the converse
is not true, and EGFR amplification does
not appear to require EGFRvIII to be a
driver of GBM pathogenesis. It therefore
remains to be seen whether blockade
of EGFRvIII-STAT signaling will be effica-
cious in the absence of simultaneous
targeting of signal transduction caused
by WT EGFR. Even with these questions
outstanding, the work by Fan et al. paves
the way for a new look at the vexing prob-
lem of EGFRvIII signaling in GBM.
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